The article reports on the posed challenges to private companies by the fallout of failed clinical trials and how they responded. Topics mentioned include the learning opportunity created by the study failure in product innovation cycle, the making of appropriate adjustments in thgeir business and research plan, and the example in Ocular Therapeutix where the stocks fell after the announcement of the phase three trial studies on Dextenza drug.